You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Rizvi N, Chaft J, Balmanoukian A, et al
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
Journal for ImmunoTherapy of Cancer 2015;3:P193. doi: 10.1186/2051-1426-3-S2-P193